Round two of the $19.75 million Clinical Translation and Commercialisation Medtech (CTCM) program is now open for applications. The CTCM program is open to Australian small to medium-sized enterprises (SMEs) and offers funding between $250,000 to $1.5 million to support early clinical development of medical devices with commercial potential.
To be considered for funding, projects must focus on the development of a medical device for human use, the purpose of which is to diagnose, prevent, monitor, treat or alleviate a disease or injury, or modify or monitor anatomy or physiological functions of the body.
Funding will only be awarded to projects where the device’s capability has already been validated with research and/or preclinical studies.
Applicants will be required to provide a co-contribution dependent on the total amount of CTCM funding requested. Additional cash or in-kind contributions above this threshold will be viewed favourably.
For further information including funding guidelines and a podcast and on-demand video of the recent round two information session, please visit the website.
Applications must be made online via Smartygrants by Friday 7 October 2022 at 4:00pm AEDT.